المؤلفون: A. K. Kalashnikova, D. D. Eliseeva, N. A. Andreeva, N. V. Zhorzholadze, I. A. Ronzina, R. Ts. Bembeeva, N. N. Venediktova, M. R. Kalganova, N. L. Sheremet, А. К. Калашникова, Д. Д. Елисеева, Н. А. Андреева, Н. В. Жоржоладзе, И. А. Ронзина, Р. Ц. Бембеева, Н. Н. Венедиктова, М. Р. Калганова, Н. Л. Шеремет

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 3 (2024); 52-57 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 3 (2024); 52-57 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-3

مصطلحات موضوعية: оптическая когерентная томография, neuromyelitis optica spectrum disorders, a disease associated with the presence of antibodies against myelin oligodendrocyte glycoproteins, multiple sclerosis, demyelinating diseases, optical coherence tomography, заболевание спектра оптиконевромиелита, расстройство, ассоциированное с наличием антител к миелиновым олигодендроцитарным гликопротеинам, рассеянный склероз, демиелинизирующие заболевания

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/2287/1674Test; Petzold A, Fraser CL, Abegg M, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022 Dec;21(12):1120-34. doi:10.1016/S1474-4422(22)00200-9. Epub 2022 Sep 27.; Sarkar P, Mehtani A, Gandhi HC, et al. Atypical optic neuritis: An overview. Indian J Ophthalmol. 2021 Jan;69(1):27-35. doi:10.4103/ijo.IJO_451_20; Zhang Y, Qiu W, Guan H, et al. Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Front Neurol. 2022 Mar 2;13:844155. doi:10.3389/fneur.2022.844155; Шерман МА, Бойко АН. Эпидемиология заболеваний спектра оптиконейромиелита. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2021;121(7-2):5-12. doi:10.17116/jnevro20211210725; Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Mar;22(3):268-82. doi:10.1016/S1474-4422(22)00431-8. Epub 2023 Jan 24.; Cacciaguerra L, Flanagan EP. Updates in NMOSD and MOGAD Diagnosis and Treatment: A Tale of Two Central Nervous System Autoimmune Inflammatory Disorders. Neurol Clin. 2024 Feb;42(1):77-114. doi:10.1016/j.ncl.2023.06.009. Epub 2023 Aug 7.; Gaier ED, Boudreault K, Rizzo JF 3rd, et al. Atypical Optic Neuritis. Curr Neurol Neurosci Rep. 2015 Dec;15(12):76. doi:10.1007/s11910-015-0598-1; Lin TY, Chien C, Lu A, et al. Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review. Expert Rev Neurother. 2021 Oct;21(10):1101-23. doi:10.1080/14737175.2021.1982697. Epub 2021 Oct 11.; Chen JJ, Sotirchos ES, Henderson AD, et al. OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG anti body-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. Mult Scler Relat Disord. 2022 Feb;58:103525. doi:10.1016/j.msard.2022.103525. Epub 2022 Jan 11.; Patil SA, Grossman S, Kenney R, et al. Where's the Vision? The Importance of Visual Outcomes in Neurologic Disorders: The 2021 H. Houston Merritt Lecture. Neurology. 2023 Jan 31;100(5):244-53. doi:10.1212/WNL.0000000000201490. Epub 2022 Dec 15.; Jarius S, Aktas O, Ayzenberg I, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) — revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023 Jul;270(7):3341-68. doi:10.1007/s00415-023-11634-0. Epub 2023 Apr 6.; Dhar N, Kumar M, Tiwari A, et al. Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: A prospective observational study. J Neurosci Rural Pract. 2023 Apr-Jun;14(2):239-51. doi:10.25259/JNRP_8_2022. Epub 2023 Feb 23.; Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017 Apr 1;389(10076):1336-46. doi:10.1016/S0140-6736(16)30959-X. Epub 2016 Nov 24.; Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi:10.1212/WNL.0000000000001729. Epub 2015 Jun 19.; Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018 May 3;15(1):134. doi:10.1186/s12974-018-1144-2; Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40. doi:10.1212/NXI.0000000000000040; Kümpfel T, Giglhuber K, Aktas O, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) — revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024 Jan;271(1):141-76. doi:10.1007/s00415-023-11910-z. Epub 2023 Sep 7. Erratum in: J Neurol. 2024 Apr 5.; Outteryck O, Majed B, Defoort-Dhellemmes S, et al. A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler. 2015 Dec;21(14):1781-93. doi:10.1177/1352458515578888. Epub 2015 Mar 31.; Oertel FC, Sotirchos ES, Zimmermann HG, et al; with the GJCF International Clinical Consortium for NMOSD and the CROCTINO study group. Longitudinal Retinal Changes in MOGAD. Ann Neurol. 2022 Sep;92(3):476-85. doi:10.1002/ana.26440. Epub 2022 Jul 16.; https://nnp.ima-press.net/nnp/article/view/2287Test

الإتاحة: https://doi.org/10.14412/2074-2711-2024-3-52-5710.14412/2074-2711-2024-310.1016/S1474-4422Test(22)00200-910.4103/ijo.IJO_451_2010.3389/fneur.2022.84415510.17116/jnevro2021121072510.1016/S1474-4422(22)00431-810.1016/j.ncl.2023.06.00910.1007/s11910-015-0598-110.1080/14737175.2021.198269710.1016/j.msard.2022.10352510.1007/s00415-023-11634-010.25259/JNRP_8_202210.1016/S0140-6736(16)30959-X10.1212/WNL.000000000000172910.1186/s12974-018-1144-210.1212/NXI.000000000000004010.1007/s00415-023-11910-z10.1177/135245851557888810.1002/ana.26440
https://nnp.ima-press.net/nnp/article/view/2287Test

المؤلفون: N. L. Sheremet, D. D. Eliseeva, V. V. Bryukhov, N. A. Andreeva, N. V. Zhorzholadze, Yu. K. Murakhovskaya, A. K. Kalashnikova, M. N. Zakharova, Н. Л. Шеремет, Д. Д. Елисеева, В. В. Брюхов, Н. А. Андреева, Н. В. Жоржоладзе, Ю. К. Мураховская, А. К. Калашникова, М. Н. Захарова

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15 (2023): (Suppl. 1); 35-42 ; Неврология, нейропсихиатрия, психосоматика; Vol 15 (2023): (Suppl. 1); 35-42 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-0

مصطلحات موضوعية: магнитно-резонансная томография, demyelination, multiple sclerosis, neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody- associated disease, optical coherence tomography, magnetic resonance imaging, демиелинизация, рассеянный склероз, заболевания спектра оптиконевромиелита, заболевания центральной нервной системы, ассоциированные с антителами к миелинолигодендроцитарному гликопротеину, оптическая когерентная томография

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/2077/1573Test; Bennett J, Costello F, Chen J, et al. Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. Lancet Neurol. 2023 Jan;22(1):89-100. doi:10.1016/S1474-4422(22)00187-9; Jenkins TM, Toosy AT. Optic neuritis: the eye as a window to the brain. Curr Opin Neurol. 2017 Feb;30(1):61-6. doi:10.1097/WCO.0000000000000414; Gaier ED, Boudreault K, Rizzo JF 3rd, et al. Atypical Optic Neuritis. Curr Neurol Neurosci Rep. 2015 Dec;15(12):76. doi:10.1007/s11910-015-0598-1; McGinley P, Goldschmidt, C, Rae-Grant A. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021 Feb 23;325(8):765-79. doi:10.1001/jama.2020.26858; Zhang Y, Qiu W, Guan H, et al. Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Front Neurol. 2022 Mar 2;13:844155. doi:10.3389/fneur.2022.844155; Foo R, Yau C, Singhal S, et al. Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore. Asia Pac J Ophthalmol (Phila). 2022 Mar-Apr 01;11(2):184-95. doi:10.1097/APO.0000000000000513; Lennon V, Wingerchuk D, Kryzer T, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004 Dec 11-17;364(9451):2106-12. doi:10.1016/S0140-6736(04)17551-X; Lennon V, Kryzer T, Pittock S, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473-7. doi:10.1084/jem.20050304; Häusser-Kinzel S, Weber M. The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. Front Immunol. 2019 Feb 8;10:201. doi:10.3389/fimmu.2019.00201; Jacob A, McKeon I, Nakashima, D, et al. Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):922-30. doi:10.1136/jnnp-2012-302310; Wingerchuk D, Banwell B, Bennett J, et al. International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi:10.1212/WNL.0000000000001729; Hamid S, Whittam D, Mutch K, et al. What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol. 2017 Oct;264(10):2088-94. doi:10.1007/s00415-017-8596-7; Flanagan B. Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases. Contin Lifelong Learn Neurol. 2019;25:815-44. doi:10.1212/CON.0000000000000742; Pröbstel A, Rudolf G, Dornmair K, et al. Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflammation. 2015;12:46. doi:10.1186/s12974-015-0256-1; Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014 Feb 11;82(6):474-81. doi:10.1212/WNL.0000000000000101. Epub 2014 Jan 10.; Peschl P, Schanda K, Zeka B, et al. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination. J Neuroinflammation. 2017 Oct 25;14(1):208. doi:10.1186/s12974-017-0984-5; Waters P, Fadda G, Woodhall M, et al. Canadian Pediatric Demyelinating Disease Network. Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. JAMA Neurol. 2020 Jan 1;77(1):82-93. doi:10.1001/jamaneurol.2019.2940; Jarius S, Metz I, Konig F, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case. Mult Scler. 2016 Oct;22(12):1541-9. doi:10.1177/1352458515622986; Sechi E, Cacciaguerra L, Chen J, et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol. 2022 Jun 17;13:885218. doi:10.3389/fneur.2022.885218; Wildemann B, Horstmann S, Korporal-Kuhnke M, et al. Aquaporin-4-und Myelin-Oligodendrozyten-Glykoprotein-Antikörper-assoziierte Optikusneuritis: Diagnose und Therapie [Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis: Diagnosis and Treatment]. Klin Monbl Augenheilkd. 2020 Nov;237(11):1290-305. doi:10.1055/a-1219-7907 (In Germ.)].; Tanaka S, Hashimoto B, Izaki S, et al. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody- positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts. Mult Scler Relat Disord. 2020 Jun;41:102005. doi:10.1016/j.msard.2020.102005; Akaishi T, Takahashi T, Misu T, et al. Difference in the Source of Anti-AQP4-IgG and Anti-MOG-IgG Antibodies in CSF in Patients With Neuromyelitis Optica Spectrum Disorder. Neurology. 2021 Jul 6;97(1):e1-e12. doi:10.1212/WNL.0000000000012175; Beck R, Cleary P, Backlund J, et al. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994 Nov;101(11):1771-8. doi:10.1016/s0161-6420(94)31103-1; Llufriu S, Castillo J, Blanco Y, et al. Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. Neurology. 2009 Sep 22;73(12):949-53. doi:10.1212/WNL.0b013e3181b879be; Roesner S, Appel R, Gbadamosi J, et al. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand. 2012 Aug;126(2):103-8. doi:10.1111/j.1600-0404.2011.01612.x. Epub 2011 Nov 2.; Banwell B, Bennett J, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Mar;22(3):268-82. doi:10.1016/S1474-4422(22)00431-8; Jurynczyk M, Messina S, Woodhall R, et al. Clinical presentation and prognosis in MOGantibody disease: a UK study. Brain. 2017 Dec 1;140(12):3128-38. doi:10.1093/brain/awx276. Erratum in: Brain. 2018 Apr 1;141(4):e31.; Kurane K, Monden Y, Tanaka D, et al. MOG-Ab titer-guided approach for steroid tapering to prevent relapse in children with mog antibody-associated adem diseases: A case report. Mult Scler Relat Disord. 2020 Oct;45:102320. doi:10.1016/j.msard.2020.102320; Deneve M, Biotti D, Patsoura S, et al. MRI features of demyelinating disease associated with anti-MOG antibodies in adults. J Neuroradiol. 2019 Sep;46(5):312-8. doi:10.1016/j.neurad.2019.06.001. Epub 2019 Jun 20.; Salama S, Khan M, Shanechi A, et al. MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler. 2020 Dec;26(14):1854-65. doi:10.1177/1352458519893093. Epub 2020 Jan 15.; Havla J, Pakeerathan T, Schwake C, et al. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well? J Neuroinflammation. 2021 May 29;18(1):121. doi:10.1186/s12974-021-02160-9; Dutra B, da Rocha A, Nunes R, et al. Neuromyelitis Optica Spectrum Disorders: Spectrum of MR Imaging Findings and Their Differential Diagnosis. Radiographics. 2018 Jan-Feb;38(1):169-93. doi:10.1148/rg.2018170141; Carandini T, Sacchi L, Bovis F, et al. Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. Mult Scler Relat Disord. 2021 Sep;54:103118. doi:10.1016/j.msard.2021.103118; Filippatou A, Mukharesh L, Saidha S, et al. AQP4-IgG and MOG-IgG Related Optic Neuritis-Prevalence, Optical Coherence Tomography Findings, and Visual Outcomes: A Systematic Review and Meta-Analysis. Front Neurol. 2020 Oct 8;11:540156. doi:10.3389/fneur.2020.540156; Sotirchos E, Filippatou A, Fitzgerald K, et al. Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler. 2020 Oct;26(11):1360-71. doi:10.1177/1352458519864928; Akaishi T, Takahashi T, Fujihara K, et al. Impact of comorbid Sjögren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol. 2021 May;268(5):1938-44. doi:10.1007/s00415-020-10377-6; Wang X, Shi Z, Zhao Z, et al. The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases. Front Immunol. 2022 Sep29;13:959469. doi:10.3389/fimmu.2022.959469; https://nnp.ima-press.net/nnp/article/view/2077Test

الإتاحة: https://doi.org/10.14412/2074-2711-2023-1S-35-42Test
https://doi.org/10.14412/2074-2711-2023-0Test
https://doi.org/10.1016/S1474-4422Test(22)00187-9
https://doi.org/10.1097/WCO.0000000000000414Test
https://doi.org/10.1007/s11910-015-0598-1Test
https://doi.org/10.1001/jama.2020.26858Test
https://doi.org/10.3389/fneur.2022.844155Test
https://doi.org/10.1097/APO.0000000000000513Test
https://doi.org/10.1016/S0140-6736Test(04)17551-X
https://doi.org/10.1084/jem.20050304Test

المؤلفون: N. A. Andreeva, N. L. Sheremet, Yu. K. Murakhovskaya, A. A. Dayal, A. A. Minin, Н. А. Андреева, Н. Л. Шеремет, Ю. К. Мураховская, А. А. Даял, А. А. Минин

المصدر: Ophthalmology in Russia; Том 18, № 3S (2021); 646-653 ; Офтальмология; Том 18, № 3S (2021); 646-653 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2021-3S

مصطلحات موضوعية: активация митофагии, Leber’s hereditary optic neuropathy, hereditary optic neuropathies, mitophagy, autophagy, mitophagy activation, autophagy activation, наследственная оптическая нейропатия Лебера, наследственные оптические нейропатии, митофагия, аутофагия

وصف الملف: application/pdf

العلاقة: https://www.ophthalmojournal.com/opht/article/view/1635/878Test; Nicholls D.G., Budd S.L. Mitochondria and neuronal survival. Physiol Rev. 2000;80(1):315–360. DOI:10.1152/physrev.2000.80.1.315; Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148(6):1145–1159. DOI:10.1016/j.cell.2012.02.035; Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–257. DOI:10.1038/bjc.1972.33; Bernardi P. Mitochondrial transport of cations: Channels, exchangers, and permeability transition. Physiol. Rev. 1999;79(4):1127–1155. DOI:10.1152/physrev.1999.79.4.1127; Gorman G.S., Chinnery P.F., DiMauro S., Hirano M., Koga Y., McFarland R., Suomalainen A., Thorburn D.R., Zeviani M., Turnbull D.M. Mitochondrial diseases. Nat Rev Dis Primers 2016;2:16080. DOI:10.1038/nrdp.2016.80; Keogh M.J., Chinnery P.F. Mitochondrial DNA mutations in neurodegeneration. Biochim Biophys Acta. 2015;1847(11):1401–1411. DOI:10.1016/j.bbabio.2015.05.015; Carroll J., Fearnley Ian M., Skehel J. Mark, Shannon Richard J., Hirst J, John E. Walker. Bovine Complex I Is a Complex of 45 Different Subunits. J. Biol. Chem. 2006;281:32724–32727. DOI:10.1074/jbc.M607135200; Benard G., Faustin B., Passerieux E., Galinier A., Rocher C., Bellance N., Delage J.-P., Casteilla L., Letellier T., Rossignol R. Physiological diversity of mitochondrial oxidative phosphorylation. Am. J. Physiol. Cell Physiol. 2006;291:1172–1182. DOI:10.1152/ajpcell.00195.2006; Taylor R.W., Turnbull D.M. Mitochondrial DNA mutations in human disease. Nat Rev Genet. 2005;6(5):389–402. DOI:10.1038/nrg1606; DiMauro S., Schon E.A. Mitochondrial disorders in the nervous system. Annu Rev Neurosci. 2008;31:91–123. DOI:10.1146/annurev.neuro.30.051606.094302; Wallace D.C. Mitochondrial DNA mutations in disease and aging. Environ Mol Mutagen. 2010;51(5):440–450. DOI:10.1002/em.20586; Stenton S.L., Prokisch H. Genetics of mitochondrial diseases: Identifying mutations to help diagnosis. EBioMedicine. 2020;56:102784. DOI:10.1016/j.ebiom.2020.102784; Chow J., Rahman J., Achermann J.C., Dattani M.T., Rahman S. Mitochondrial disease and endocrine dysfunction. Nat Rev Endocrinol. 2017;13(2):92–104. DOI:10.1038/nrendo.2016.151; Глоба О.В., Журкова Н.В., Кондакова О.Б., Тихомиров Е.Е., Басаргина Е.Н., Семенова Н.Ю., Маслова О.И., Кузенкова Л.М., Пинелис В.Г. Клинический полиморфизм митохондриальной дисфункции у детей. Современные проблемы науки и образования. 2008;4:52–53.; Carelli V., Ross-Cisneros F.N., Sadun A.A. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res. 2004;23(1):53–89. DOI:10.1016/j.preteyeres.2003.10.003; Wong-Riley M.T. Energy metabolism of the visual system. Eye Brain. 2010;2:99–116. DOI:10.2147/EB.S9078; Niven J.E., Laughlin S.B. Energy limitation as a selective pressure on the evolution of sensory systems. Journal of Experimental Biology. 2008;211(11):1792–1804. DOI:10.1242/jeb.017574; Chhetri J., Gueven N. Targeting mitochondrial function to protect against vision loss. Expert Opin Ther Targets. 2016;20(6):721–736. DOI:10.1517/14728222.2015.1134489; Fraser J.A., Biousse V., Newman N.J. The neuro-ophthalmology of mitochondrial disease. Surv Ophthalmol. 2010;55(4):299–334. DOI:10.1016/j.survophthal.2009.10.002; Kim U.S., Jurkute N., Yu-Wai-Man P. Leber Hereditary Optic Neuropathy-Light at the End of the Tunnel. Asia Pac J Ophthalmol (Phila). 2018;7(4):242–245. DOI:10.22608/APO.2018293; Yu-Wai-Man P., Griffiths P., Chinnery P.F. Mitochondrial optic neuropathies — Disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011;30(22):81–114. DOI:10.1016/j.preteyeres.2010.11.002; Шеремет Н.Л., Андреева Н.А., Шмелькова М.С., Цыганкова П.Г. Митохондриальный биогенез при наследственных оптических нейропатиях. Вестник офтальмологии. 2019;135(5):85–91. DOI:10.17116/oftalma201913505185; Lemasters J.J. Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging. Rejuvenation Res. 2005;8(1):3–5. DOI:10.1089/rej.2005.8.3; Skeie J.M., Nishimura D.Y., Wang C.L., Schmidt G.A., Aldrich B.T., Greiner M.A. Mitophagy: An Emerging Target in Ocular Pathology. Investigative Ophthalmology & Visual Science. 2021;62(3):22. DOI:10.1167/iovs.62.3.22; Dikic I., Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19(6):349–364. DOI:10.1038/s41580-018-0003-4; Mizushima N., Ohsumi Y., Yoshimori T. Autophagosome formation in mammalian cells. Cell Struct Funct. 2002 ;27(6):421–429. DOI:10.1247/csf.27.421; Khaminets A., Behl C., Dikic I. Khaminets A, Behl C, Dikic I. Ubiquitin-Dependent And Independent Signals In Selective Autophagy. Trends Cell Biol. 2016;26(1):6–16. DOI:10.1016/j.tcb.2015.08.010; Shen Z., Li Y., Gasparski A.N., Abeliovich H., Greenberg M.L. Cardiolipin Regulates Mitophagy through the Protein Kinase C Pathway. J Biol Chem. 2017;292(7):2916–2923. DOI:10.1074/jbc.M116.753574; Baixauli F., López-Otín C., Mittelbrunn M. Exosomes and autophagy: coordinated mechanisms for the maintenance of cellular fitness. Front Immunol. 2014;5:403. DOI:10.3389/fimmu.2014.00403; Palikaras K., Lionaki E., Tavernarakis N. Mechanisms of mitophagy in cellular homeostasis, physiology and pathology. Nat Cell Biol. 2018;20(9):1013–1022. DOI:10.1038/s41556-018-0176-2; Takatori S., Ito G., Iwatsubo T. Cytoplasmic localization and proteasomal degradation of N-terminally cleaved form of PINK1. Neurosci Lett. 2008;430(1):13–17. DOI:10.1016/j.neulet.2007.10.019; Wanderoy S., Hees J.T., Klesse R., Edlich F., Harbauer A.B. Kill one or kill the many: interplay between mitophagy and apoptosis. Biol Chem. 2020;402(1):73–88. DOI:10.1515/hsz-2020-0231; Schweers R.L., Zhang J., Randall M.S., Loyd M.R., Li W., Dorsey F.C., Kundu M., Opferman J.T., Cleveland J.L., Miller J.L., Ney P.A. NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci USA. 2007;104(49):19500–19505. DOI:10.1073/pnas.0708818104; Chandel N.S., Jasper H., Ho T.T., Passegué E. Metabolic regulation of stem cell function in tissue homeostasis and organismal ageing. Nat Cell Biol. 2016;18(8):823–832. DOI:10.1038/ncb3385; Zhang H., Bosch-Marce M., Shimoda L.A., Tan Y.S, Baek J.H., Wesley J.B., Gonzalez F.J., Semenza G.L. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem. 2008;283(16):10892–10903. DOI:10.1074/jbc.M800102200; Esteban-Martínez L., Sierra-Filardi E., McGreal R.S., Salazar-Roa M., Mariño G., Seco E., Durand S., Enot D., Graña O., Malumbres M., Cvekl A., Cuervo A.M., Kroemer G., Boya P. Programmed mitophagy is essential for the glycolytic switch during cell differentiation. EMBO J. 2017 Jun 14;36(12):1688–1706. DOI:10.15252/embj.201695916; Lathrop K.L., Steketee M.B. Mitochondrial dynamics in retinal ganglion cell axon regeneration and growth cone guidance. Journal of ocular biology. 2013;1(2):9.; Kisilevsky E., Freund P., Margolin E. Mitochondrial disorders and the eye. Surv Ophthalmol. 2020;65(3):294–311. DOI:10.1016/j.survophthal.2019.11.001; King M.P., Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 1989;246(4929):500–503. DOI:10.1126/science.2814477; Kirches E. LHON: Mitochondrial Mutations and More. Curr Genomics. 2011;12(1):44–54. DOI:10.2174/138920211794520150; Ghelli A., Zanna C., Porcelli A.M., Schapira A.H., Martinuzzi A., Carelli V., Rugolo M. Leber’s hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium. J Biol Chem. 2003;278(6):4145–4150. DOI:10.1074/jbc.M210285200; Giordano C., Iommarini L., Giordano L., Maresca A., Pisano A., Valentino M.L., Caporali L., Liguori R., Deceglie S., Roberti M., Fanelli F. Efficient mitochondrial biogenesis drives incomplete penetrance in Leber’s hereditary optic neuropathy. Brain. 2014;137(Pt 2):335–353. DOI:10.1093/brain/awt343; Zhang J., Ji Y., Lu Y., Fu R., Xu M., Liu X., Guan M.X. Leber’s hereditary optic neuropathy (LHON)-associated ND5 12338T>C mutation altered the assembly and function of complex I, apoptosis and mitophagy. Hum Mol Genet. 2018;27(11):1999–2011. DOI:10.1093/hmg/ddy107; Sharma L.K., Tiwari M., Rai N.K., Bai Y. Mitophagy activation repairs Leber’s hereditary optic neuropathy-associated mitochondrial dysfunction and improves cell survival. Human molecular genetics. 2019;28(3):422–433. DOI:10.1093/hmg/ddy354; Kodroń A., Hajieva P., Kulicka A., Paterczyk B., Jankauskaite E., Bartnik E. Analysis of BNIP3 and BNIP3L/Nix expression in cybrid cell lines harboring two LHONassociated mutations. Acta Biochim Pol. 2019;66(4):427–435. DOI:10.18388/abp.2019_2837; Dai Y., Zheng K., Clark J., Swerdlow R.H., Pulst S.M., Sutton J.P., Shinobu L.A., Simon D.K. Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation. Hum Mol Genet. 2014;23(3):637–647. DOI:10.1093/hmg/ddt450; Hoekstra R.F. Evolutionary origin and consequences of uniparental mitochondrial inheritance. Human Reproduction. 2000;15 Suppl. 2:102–111. DOI:10.1093/humrep/15.suppl_2.102; Wei Y., Huang J. Role of estrogen and its receptors mediated-autophagy in cell fate and human diseases. J Steroid Biochem Mol Biol. 2019;191:105–380. DOI:10.1016/j.jsbmb.2019.105380; Pisano A., Preziuso C., Iommarini L., Perli E., Grazioli P., Campese A.F., Maresca A., Montopoli M., Masuelli L., Sadun A.A., d’Amati G., Carelli V., Ghelli A., Giordano C. Targeting estrogen receptor β as preventive therapeutic strategy for Leber›s hereditary optic neuropathy. Hum Mol Genet. 2015;24(24):6921–6931. DOI:10.1093/hmg/ddv396; Djajadikerta A., Keshri S., Pavel M., Prestil R., Ryan L., Rubinsztein D.C. Autophagy Induction as a Therapeutic Strategy for Neurodegenerative Diseases. J Mol Biol. 2020;432(8):2799–2821. DOI:10.1016/j.jmb.2019.12.035; Пупышев А.Б., Короленко Т.А., Тихонова М.А. Терапевтическая мишень торможения нейродегнерации: Аутофагия. Журнал высшей нервной деятельности 2016;66(5):515–554. DOI:10.1007/s11055-017-0519-7; Yu A.K., Datta S., McMackin M.Z., Cortopassi G.A. Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules. Hum Mol Genet. 2017;26(24):4929–4936. DOI:10.1093/hmg/ddx373; Johnson S.C., Yanos M.E., Kayser E.B., Quintana A., Sangesland M., Castanza A., Uhde L., Hui J., Wall V.Z., Gagnidze A., Oh K., Wasko B.M., Ramos F.J., Palmiter R.D., Rabinovitch P.S., Morgan P.G., Sedensky M.M., Kaeberlein M. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science. 2013;342(6165):1524–1528. DOI:10.1126/science.1244360; Rodríguez-Navarro J.A., Rodríguez L., Casarejos M.J., Solano R. M., Gómez A., Perucho J., Cuervo A.M., García de Yébenes J., Mena M.A. Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation. Neurobiology of disease. 2010;39(3), 423–438. DOI:10.1016/j.nbd.2010.05.014; Pupyshev A.B., Tikhonova M.A., Akopyan A.A., Tenditnik M.V., Dubrovina N.I., Korolenko T.A. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson’s disease. Pharmacol Biochem Behav. 2019;177:1–11. DOI:10.1016/j.pbb.2018.12.005; Chao de la Barca J.M., Simard G., Amati-Bonneau P., Safiedeen Z., Prunier-Mirebeau D., Chupin S., Gadras C., Tessier L., Gueguen N., Chevrollier A., DesquiretDumas V. The metabolomic signature of Leber’s hereditary optic neuropathy reveals endoplasmic reticulum stress. Brain. 2016;139(11):2864–2876. DOI:10.1093/brain/aww222; Büttner S., Broeskamp F., Sommer C., Markaki M., Habernig L., Alavian-Ghavanini A., Carmona-Gutierrez D., Eisenberg T., Michael E., Kroemer G., Tavernarakis N., Sigrist S.J., Madeo F. Spermidine protects against α-synuclein neurotoxicity. Cell Cycle. 2014;13(24):3903–3908. DOI:10.4161/15384101.2014.973309; Wei Q., Hu W., Lou Q., Yu J. NAD+ inhibits the metabolic reprogramming of RPE cells in early AMD by upregulating mitophagy. Discov Med. 2019;27(149):189–196.; Hou Y., Lautrup S., Cordonnier S., Wang Y., Croteau D.L., Zavala E., Zhang Y., Moritoh K., O’Connell J.F., Baptiste B.A., Stevnsner T.V., Mattson M.P., Bohr V.A. NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci USA. 2018;115(8):E1876–E1885. DOI:10.1073/pnas.1718819115; https://www.ophthalmojournal.com/opht/article/view/1635Test

الإتاحة: https://doi.org/10.18008/1816-5095-2021-3S-646-653Test
https://doi.org/10.18008/1816-5095-2021-3STest
https://doi.org/10.1152/physrev.2000.80.1.315Test
https://doi.org/10.1016/j.cell.2012.02.035Test
https://doi.org/10.1038/bjc.1972.33Test
https://doi.org/10.1152/physrev.1999.79.4.1127Test
https://doi.org/10.1038/nrdp.2016.80Test
https://doi.org/10.1016/j.bbabio.2015.05.015Test
https://doi.org/10.1074/jbc.M607135200Test
https://doi.org/10.1152/ajpcell.00195.2006Test

المؤلفون: N. A. Andreeva, E. V. Kumirova, Н. А. Андреева, Э. В. Кумирова

المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 5, № 4 (2018); 51-59 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 5, № 4 (2018); 51-59 ; 2413-5496 ; 2311-1267 ; 10.17650/2311-1267-2018-5-4

مصطلحات موضوعية: орексин, sleep disorders, insomnia, CNS tumors, insomnia therapy, orexin, нарушения сна, инсомния, опухоли центральной нервной системы, терапия инсомнии

وصف الملف: application/pdf

العلاقة: https://journal.nodgo.org/jour/article/view/441/423Test; Badin E., Haddad C., Shatkin J.P. Insomnia: the sleeping giant of pediatric public health. Curr Psychiatry Rep 2016;18(5):47. doi:10.1007/s11920-016-0687-0.; Mai E., Buysse D.J. Insomnia: prevalence, impact, pathogenesis, diff erential diagnosis, and evaluation. Sleep Med Clin 2008;3(2):167–74. doi:10.1016/j.jsmc.2008.02.001.; Zhou E.S., Manley P.E., Marcus K.J., Recklitis C.J. Medical and Psychosocial Correlates of Insomnia Symptoms in Adult Survivors of Pediatric Brain Tumors. J Pediatr Psychol 2016;41(6):623–30. doi:10.1093/jpepsy/jsv071.; Graci G. Pathogenesis and management of cancer-related insomnia. J Support Oncol 2005;3(5):349–59. PMID: 16218258.; Walter L.M., Nixon G.M., Davey M.J., Downie P.A., Horne R.S. Sleep and fatigue in pediatric oncology: A review of the literature. Sleep Med Rev 2015;24:71–82. doi:10.1016/j.smrv.2015.01.001.; Bruni O., Angriman M. Pediatric insomnia: new insights in clinical assessment and treatment options. Arch Ital Biol 2015;153(2–3):144–56. doi:10.12871/000398292015239.; Kales A., Rechtschaff en A. A manual of standardized terminology, techniques and scoring system for sleep stages in human subjects. NIH Publication 204. US Government Printing Offi ce, Washington, DC, 1968.; Berry R.B., Brooks R., Gamaldo C., Harding S.M., Lloyd R.M., Quan S.F., Troester M.T., Vaughn B.V. AASM scoring manual updates for 2017 (version 2.4). J Clin Sleep Med 2017;13(5):665–6. doi:10.5664/jcsm.6576.; Bradley’s Neurology in Clinical Practice, 7th edition: Daroff R.B., Jankovic J., Mazziotta J.C., Pomeroy S.L., 2016.; Нейробиология сна: современный взгляд. Учебное пособие под ред. Петрова А.М., Гиниатуллина А.Р. Казань: КГМУ, 2012. [Neurobiology of sleep: a modern look. Textbook, ed. Petrov A.M., Giniatullin A.R. Kazan: KGMU, 2012. (In Russ.)].; Ковальзон В.М. Роль орексинергической системы мозга в регуляции бодрствования и сна. Эффективная фармакотерапия 2016;19:6–14. [Kovalzon V.M. The role of the orexinergic system of the brain in the regulation of wakefulness and sleep. Eff ektivnaya farmakoterapiya = Eff ective Pharmacotherapy 2016;19:6–14. (In Russ.)].; Savvidis C., Koutsilieris M. Circadian Rhythm Disruption in Cancer Biology. Mol Med 2012;18(1):1249–60. doi:10.2119/molmed.2012.00077.; International Classifi cation of Sleep Disorders, 3rd edition. Darien, IL USA: American Academy of Sleep Medicine, 2014.; American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders, 5th edition, 2013. 992 p.; Robertson M.E., McSherry F., Herndon J.E., Peters K.B. Insomnia and its associations in patients with recurrent glial neoplasms. Springerplus 2016:5(1):823. doi:10.1186/s40064-016-2578-6.; Ciriaco M., Ventrice P., Russo G., Scicchitano M., Mazzitello G., Scicchitano F., Russo E. Corticosteroid-related central nervous system side eff ects. J Pharmacol Pharmacother 2013;4(5):94–8. doi:10.4103/0976-500X.120975.; Sateia M.J., Buysse D.J., Krystal A.D., Neubauer D.N., Heald J.L. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017;13(2):307–49. doi:10.5664/jcsm.6470.; Румянцев А.Г., Масчан А.А., Жуковская Е.В. и др. Детская гематология. Сборник клинических рекомендаций. М.: ГЭОТАР-Медиа, 2015. 656 c. [Rumyantsev A.G., Maschan A.A., Zhukovskaya E.V. et al. Pediatric Hematology. Collection of clinical guidelines. M.: GEOTAR-Media, 2015. 656 p. (In Russ.)].; Формуляр лекарственных средств в паллиативной педиатрии. Под ред. С. Джессэл и др. Пер. с англ. и редакция русской версии – Э.В. Кумирова. М.: Издательство «Проспект», 2013. 112 с. [Formulary of medicines in palliative pediatrics. Ed. S. Jessel et al. from english and editors of the russian version – E.V. Kumirova. M.: Prospect Publishing House, 2013. 112 p. (In Russ.)].; Kawabe K., Horiuchi F., Ochi M., Nishimoto K., Ueno S., Oka Y. Suvorexant for the Treatment of Insomnia in Adolescents. J Child Adolesc Psychopharmacol 2017;27(9):792–5. doi:10.1089/cap.2016.0206.; https://journal.nodgo.org/jour/article/view/441Test

الإتاحة: https://doi.org/10.17650/2311-1267-2018-5-4-51-59Test
https://doi.org/10.17650/2311-1267-2018-5-4Test
https://doi.org/10.1007/s11920-016-0687-0Test
https://doi.org/10.1016/j.jsmc.2008.02.001Test
https://doi.org/10.1093/jpepsy/jsv071Test
https://doi.org/10.1016/j.smrv.2015.01.001Test
https://doi.org/10.12871/000398292015239Test
https://doi.org/10.5664/jcsm.6576Test
https://doi.org/10.2119/molmed.2012.00077Test
https://doi.org/10.1186/s40064-016-2578-6Test

المؤلفون: E. V. Kleychuk, S. A. Mikhaylova, L. A. Zolotukhina, N. A. Andreeva, E. A. Popova, O. G. Ivchenko, Е. В. Клейчук, С. А. Михайлова, Л. А. Золотухина, Н. А. Андреева, Е. А. Попова, О. Г. Ивченко

المصدر: Pharmacy & Pharmacology; Том 2, № 6(7) (2014); 117-121 ; Фармация и фармакология; Том 2, № 6(7) (2014); 117-121 ; 2413-2241 ; 2307-9266 ; 10.19163/2307-9266-2014-2-6(7)

مصطلحات موضوعية: эффективность продаж, diuretics, antihypertensive remedies, assortment, pharmacy organizations, sales efficiency, диуретические препараты, антигипертензивные препараты, ассортимент, аптечные организации

وصف الملف: application/pdf

العلاقة: https://www.pharmpharm.ru/jour/article/view/83/147Test; Авксентьева М. В. Принципы клинико-экономических исследований // Ремедиум. – 2002. – №9. – С. 44-46.; Белоусов, Ю.Б. Оценка эффективности при длительной терапии больных ИБС / Ю.Б.Белоусов, М.В.Леонов // Кардиология. – 2003. – №4. – С. 1417.; Недогода, C.B. Фармакоэкономика артериальной гипертензии: от глобального к частному / C.B. Недогода, A.B. Сабанов // Проблемы стандартизации в здравоохранении. Бюллетень клинико-экономического анализа. – 2003. – №.2. – С.25-29.; Остроумова, О.Д. Лечение артериальной гипертонии в условиях поликлиники: клиническая и экономическая эффективность / О.Д.Остроумова, К.А.Ищенко // onsiliummedicum. – 2007. – №5. – С. 19-24.; https://www.pharmpharm.ru/jour/article/view/83Test

الإتاحة: https://doi.org/10.19163/2307-9266-2014-2-6Test(7)-117-12110.19163/2307-9266-2014-2-6(7
https://www.pharmpharm.ru/jour/article/view/83Test